Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 2
1990 2
1995 2
2007 1
2008 1
2009 1
2010 1
2014 1
2016 1
2018 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
[Introduction. Multiple sclerosis].
Antigüedad AR. Antigüedad AR. Med Clin (Barc). 2014 Dec;143 Suppl 3:1-2. doi: 10.1016/S0025-7753(15)30001-4. Med Clin (Barc). 2014. PMID: 25732941 Spanish. No abstract available.
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus.
Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, Alvarez de Arcaya A, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, de Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A. Sepúlveda M, et al. Among authors: antiguedad ar. Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225. doi: 10.1212/NXI.0000000000000225. eCollection 2016 Jun. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27144216 Free PMC article.
Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS).
Benito-León J, Martínez-Martín P, Frades B, Martínez-Ginés ML, de Andrés C, Meca-Lallana JE, Antigüedad AR, Huete-Antón B, Rodríguez-García E, Ruiz-Martínez J. Benito-León J, et al. Among authors: antiguedad ar. Mult Scler. 2007 Jun;13(5):645-51. doi: 10.1177/1352458506073528. Epub 2007 Feb 16. Mult Scler. 2007. PMID: 17548445
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group. Comi G, et al. Mult Scler. 2010 Nov;16(11):1360-6. doi: 10.1177/1352458510378127. Epub 2010 Sep 8. Mult Scler. 2010. PMID: 20834039 Clinical Trial.
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group. Comi G, et al. Lancet. 2008 Jun 21;371(9630):2085-92. doi: 10.1016/S0140-6736(08)60918-6. Lancet. 2008. PMID: 18572078 Clinical Trial.
16 results